drugset / Trial / NCT07470151
Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
Recruiting
12 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Everest Medicines (China) Co.,Ltd. · collab
NaSequentialOpen-labelTreatment
Summary
A FIH, single arm, open-label, Investigator Initiated Trial (IIT) study to evaluate the safety and tolerability of EVM18001 in the treatment of active refractory autoimmune diseases (SLE, MG, and SSc), and determine the recommended dose for subsequent treatment. At the same time, the PK/PD characteristics of EVM18001 will be evaluated, preliminary efficacy will be observed, and related biomarkers and immunogenicity will be explored.
Timeline
- Start
- 2026-03-12
- Primary completion
- 2026-11
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EVM18001 | Unknown | — | — |